Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Mylan NV (NASDAQ:MYL)

57.24
Delayed Data
As of Jul 29
 +0.89 / +1.58%
Today’s Change
44.80
Today|||52-Week Range
76.69
+1.54%
Year-to-Date
Mylan Receives Unconditional Clearance from EC on Acquisition of Perrigo
Jul 29 / Benzinga
China Tanks as Q2 Marches On - Ahead of Wall Street
Jul 27 / Zacks.com
Teva to Buy Allergan's Generics Business for $40.5B - Analyst Blog
Jul 28 / Zacks.com
Global Stocks, US Equity Futures Slide Following China Crash
Jul 27 / Investing Channel
Hikma Pharmaceuticals to Buy Generic Drug Maker Roxane for $2.65 Billion
Jul 28 / TheStreet.com
Teva buys Allergan's generic drugs business for $40.5 billion
Jul 27 / CNNMoney.com
Benzinga's M&A Chatter for Monday July 27, 2015
Jul 27 / Benzinga
Pre-Market Laggard: Mylan (MYL)
Jul 27 / TheStreet.com
Mylan Shares Tank After Teva Pharmaceutical Nixes Takeover Bid
Jul 27 / TheStreet.com
European Stocks Sharply Lower as Asian Stocks Drag
Jul 27 / TheStreet.com
3 Health Care Stocks to Trade for Gains
Jul 27 / TheStreet.com
Allergan sells generic drugs unit to Teva for $40bn
Jul 27 / FT.com
Pharma M&A: portfolio theory
Jul 27 / FT.com
Chinese Stocks Post Biggest One-Day Loss in Eight Years
Jul 27 / TheStreet.com
Weak sales outlook hits machinery makers
Jul 27 / FT.com
Drugmaker Mallinckrodt Looks Very Healthy
Jul 23 / TheStreet.com
Why Mylan N.V. Stock Slumped Today
Jul 27 / MotleyFool.com
Benzinga's Top #PreMarket Losers
Jul 23 / Benzinga
Why Teva Pharmaceutical Industries Ltd. Stock Jumped Today
Jul 27 / MotleyFool.com
Allergan Faces Patent Challenge for Eye Treatment Restasis - Analyst Blog
Jul 16 / Zacks.com
Mylan share price plunges after Teva abandons bid
Jul 27 / FT.com
Teva prepares to raise its bid for Mylan
Jul 06 / FT.com
Mylan (MYL) Stock Tanks After Teva Withdraws Takeover Bid
Jul 27 / TheStreet.com